Virus News and Research

Latest Virus News and Research

Scientists discover tumor-targeting neural stem cells

Could engineered human stem cells hold the key to cancer survival? Scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have discovered that neural stem cells possess the innate ability to target tumor cells outside the central nervous system. This finding, which was demonstrated successfully on breast cancer cells, was recently published in leading peer reviewed journal, Stem Cells.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Entire HCV lifecycle can be recapitulated in murine cells

A US study presented today at The International Liver CongressTM 2012 demonstrates that the entire HCV lifecycle can be recapitulated in murine cells, implying that HCV permissive mouse models could soon be developed.

20 Apr 2012

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.

19 Apr 2012

ESTRO 31 and the World Congress of Brachytherapy to take place from May 9-13

ESTRO 31 and the World Congress of Brachytherapy will combine to feature new research results in clinical and basic radiobiology, physics and brachytherapy, presented by top doctors and scientists from all over the world working together for the benefit of cancer patients.

19 Apr 2012

White House science adviser responds to inquiry regarding handling of H5N1 research controversy

"White House science adviser John Holdren has replied to questions asked last month by Representative Jim Sensenbrenner (R-Wisc.) about how the Obama Administration has handled the controversy surrounding two studies that showed how to make the H5N1 avian influenza virus transmissible between mammals," ScienceInsider reports.

19 Apr 2012

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Presidio Pharmaceuticals, Inc. announced results today from a Phase 1a-1b clinical trial of PPI-668, a potent, pan-genotypic HCV NS5A inhibitor being developed for the treatment of patients with chronic hepatitis C.

19 Apr 2012

Anti-HIV pill could prevent thousands of new infections: Study finds

A once daily pill to prevent HIV infection could significantly reduce the spread of the AIDS-causing virus. However it would only be cost-effective if limited to men at very high risk for HIV infection, according to a new study.

18 Apr 2012

World Bank selects U.S. nominee Jim Kim as president

"The World Bank on Monday chose Korean-born American health expert Jim Yong Kim as its new president, maintaining Washington's grip on the job and leaving developing countries frustrated with the selection process," Reuters reports (Wroughton, 4/16).

18 Apr 2012

Kaposi's sarcoma-associated herpesvirus senses and reacts to host cell's impending death

A research team led by Children's National Medical Center has identified a trigger that causes latent Kaposi's sarcoma-associated herpesvirus (KSHV) to rapidly replicate itself. KSHV causes Kaposi's sarcoma, primary effusion lymphoma, and other cancers that commonly affect immunocompromised patients, including those with AIDS.

18 Apr 2012

Allied Healthcare announces Coridon license to vector technology

Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.

17 Apr 2012

Flu outbreak at veterans home

State Veterans' Affairs Commissioner Linda Schwartz told The Associated Press that the veterans were taken to Hartford Hospital after a number began complaining of flu-like symptoms. The 18 men live at the Connecticut State Veterans Home in either the Sgt. John L. Levitow Veteran's Health Center or a residential facility.

17 Apr 2012

Virus News and Research

Latest Virus News and Research

Scientists discover tumor-targeting neural stem cells

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data provides hope for HCV non-responders

New data shows consolidation of interferon-free revolution in HCV treatment

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Entire HCV lifecycle can be recapitulated in murine cells

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

EASL publishes new clinical practice guideline on ALD

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

ESTRO 31 and the World Congress of Brachytherapy to take place from May 9-13

White House science adviser responds to inquiry regarding handling of H5N1 research controversy

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Anti-HIV pill could prevent thousands of new infections: Study finds

World Bank selects U.S. nominee Jim Kim as president

Kaposi's sarcoma-associated herpesvirus senses and reacts to host cell's impending death

Allied Healthcare announces Coridon license to vector technology

Flu outbreak at veterans home

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Virus News and Research

Latest Virus News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in